Evidence map›Paper›PMID 29704080›Full record

ArticleJournal of neuro-oncology2018

MR-spectroscopic imaging of glial tumors in the spotlight of the 2016 WHO classification.

Elie Diamandis, Carl Phillip Simon Gabriel, Urs Würtemberger, Konstanze Guggenberger, Horst Urbach, Ori Staszewski, Silke Lassmann, Oliver Schnell, Jürgen Grauvogel, Irina Mader and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 25 citations in OpenAlex.

  1. 7 Tesla magnetic resonance spectroscopic imaging predicting IDH status and glioma grading.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024
    Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Elie DiamandisDepartment of Neuroradiology, Medical Center - University of Freiburg, Freiburg, Germany.
Carl Phillip Simon GabrielDepartment of Neuroradiology, Medical Center - University of Freiburg, Freiburg, Germany.
Urs WürtembergerDepartment of Neuroradiology, Medical Center - University of Freiburg, Freiburg, Germany.
Konstanze GuggenbergerDepartment of Neuroradiology, Medical Center - University of Freiburg, Freiburg, Germany.
Horst UrbachDepartment of Neuroradiology, Medical Center - University of Freiburg, Freiburg, Germany.
Ori StaszewskiInstitute of Neuropathology, Medical Center - University of Freiburg, Freiburg, Germany.
Silke LassmannInstitute for Pathology, University of Freiburg, Freiburg, Germany.
Oliver SchnellDepartment of Neurosurgery, Medical Center - University of Freiburg, Breisacher Straße 64, 79106, Freiburg, Germany.
Jürgen GrauvogelDepartment of Neurosurgery, Medical Center - University of Freiburg, Breisacher Straße 64, 79106, Freiburg, Germany.
Irina MaderDepartment of Neuroradiology, Medical Center - University of Freiburg, Freiburg, Germany.
Dieter Henrik HeilandDepartment of Neurosurgery, Medical Center - University of Freiburg, Breisacher Straße 64, 79106, Freiburg, Germany. dieter.henrik.heiland@uniklinik-freiburg.de.ORCID http://orcid.org/0000-0002-9258-3033
University of Freiburg · DE

Funding

German Cancer Society SG TII
6 · The paper itself

Abstract

backgroundThe purpose of this study is to map spatial metabolite differences across three molecular subgroups of glial tumors, defined by the IDH1/2 mutation and 1p19q-co-deletion, using magnetic resonance spectroscopy. This work reports a new MR spectroscopy based classification algorithm by applying a radiomics analytics pipeline. MATERIALS: 65 patients received anatomical and chemical shift imaging (5 × 5 × 20 mm voxel size). Tumor regions were segmented and registered to corresponding spectroscopic voxels. Spectroscopic features were computed (n = 860) in a radiomic approach and selected by a classification algorithm. Finally, a random forest machine-learning model was trained to predict the molecular subtypes.

resultsA cluster analysis identified three robust spectroscopic clusters based on the mean silhouette widths. Molecular subgroups were significantly associated with the computed spectroscopic clusters (Fisher's Exact test p < 0.01). A machine-learning model was trained and validated by public available MRS data (n = 19). The analysis showed an accuracy rate in the Random Forest model by 93.8%.

conclusionsMR spectroscopy is a robust tool for predicting the molecular subtype in gliomas and adds important diagnostic information to the preoperative diagnostic work-up of glial tumor patients. MR-spectroscopy could improve radiological diagnostics in the future and potentially influence clinical and surgical decisions to improve individual tumor treatment.

Indexed as

Image Interpretation, Computer-AssistedMagnetic Resonance ImagingMagnetic Resonance SpectroscopyBiomarkers, TumorBrainBrain NeoplasmsCluster AnalysisGliomaHumansIsocitrate DehydrogenaseMachine LearningMutationProspective StudiesBiomarkers, TumorIDH1 protein, humanIDH2 protein, humanIsocitrate DehydrogenaseGliomaMachine-learningMagnetic resonance spectroscopyRadiogenomics

Identifiers

PMID29704080
OpenAlexW2802744593

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.